Department of Lymphoma and Myeloma, Unit 429, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Nat Rev Clin Oncol. 2011 Feb;8(2):85-96. doi: 10.1038/nrclinonc.2010.189. Epub 2010 Dec 14.
An improved understanding of the molecular biology of cancer cell growth and survival and the role of the microenvironment in supporting the survival of cancer cells, including lymphoma cells, has led to the identification of a number of potential therapeutic targets. Despite these advances, drug development for lymphoma remains slow, inefficient, and frequently unfocused. Future work should focus on identifying 'driver' molecular defects of oncogenic pathways that can be targeted therapeutically, discovering predictive biomarkers for treatment response, and prioritizing promising drugs to accelerate their approval. This Review summarizes the current development status of novel agents for lymphoma and discusses strategies to move the field forward.
对癌细胞生长和存活的分子生物学以及微环境在支持包括淋巴瘤细胞在内的癌细胞存活中的作用有了更深入的了解，这导致了一些潜在治疗靶点的确定。尽管取得了这些进展，但淋巴瘤的药物开发仍然缓慢、低效且常常缺乏重点。未来的工作应集中于确定可进行治疗靶向的致癌途径的“驱动”分子缺陷，发现治疗反应的预测性生物标志物，并优先考虑有前途的药物以加速其批准。本综述总结了目前淋巴瘤新型药物的开发状况，并讨论了推动该领域前进的策略。
